<DOC>
	<DOCNO>NCT00752986</DOCNO>
	<brief_summary>The primary objective ass event-free survival define time randomisation progression , death without progression , loss follow , whichever occur first..</brief_summary>
	<brief_title>ZACtima FASlodex Trial Postmenopausal Advance Breast Cancer Patients Instead ZACtima FASlodex Trial</brief_title>
	<detailed_description>end-point Efficacy : event-free survival ( EFS )</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Post menopausal woman locally advance metastatic breast cancer Patients may either measurable nonmeasurable disease , define RECIST criterion One previous hormone therapy one previous chemotherapy advance disease allow ( patient stable evident disease chemotherapy eligible ) estrogen receptor positive ER+ and/or progesterone receptor positive PR+ primary secondary tumour Hormone receptor negative tumour ( ER PR negative ) Presence lifethreatening metastatic visceral disease Significant cardiovascular event ( e.g . myocardial infarction , superior vena cava [ SVC ] syndrome , New York Heart Association [ NYHA ] classification heart disease ³2 ) within 3 month entry , presence cardiac disease opinion History arrhythmia QTc Bazett 's correction unmeasurable ≥ 480 msec screening ECG</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>ZD6474</keyword>
	<keyword>Vandetanib</keyword>
	<keyword>Zactima</keyword>
	<keyword>Fulvestrant</keyword>
	<keyword>Faslodex</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Advanced , Metastatic</keyword>
	<keyword>Hormone Receptor Positive</keyword>
	<keyword>Post-Menopausal Patients</keyword>
	<keyword>post-menopausal woman hormone receptor positive advance breast cancer</keyword>
</DOC>